Loading…

Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics

The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis 2011-07, Vol.55 (5), p.878-888
Main Authors: Gupta, Shalini, Devanarayan, Viswanath, Finco, Deborah, Gunn, George R., Kirshner, Susan, Richards, Susan, Rup, Bonita, Song, An, Subramanyam, Meena
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793
cites cdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793
container_end_page 888
container_issue 5
container_start_page 878
container_title Journal of pharmaceutical and biomedical analysis
container_volume 55
creator Gupta, Shalini
Devanarayan, Viswanath
Finco, Deborah
Gunn, George R.
Kirshner, Susan
Richards, Susan
Rup, Bonita
Song, An
Subramanyam, Meena
description The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007 [1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors.
doi_str_mv 10.1016/j.jpba.2011.03.038
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_868376563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708511001907</els_id><sourcerecordid>868376563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</originalsourceid><addsrcrecordid>eNqFkV2L1DAUhoso7rj6B7zQ3IjedMx3UvBGFr9gQVAXvAtpejJmaJsxaRfGf-M_NaUzerdCICE85z05earqKcFbgol8vd_uD63dUkzIFrOy9L1qQ7RiNZX8-_1qgxUjtcJaXFSPct5jjAVp-MPqghLBiKB0U_3-Ai4OA4ydnUIcM_IxoekHoFvbh_UORY8c9H3d2gwdsjnbY0bzcj7DHUzgzuwI85RK9a8w7pAdp9DG7ojCMMwjoAT5UNpARtAHF6YlcGfDmCfUhtjHXXC2XzKTPZSc4PLj6oG3fYYnp_2yunn_7tvVx_r684dPV2-va8eVmGrGWy4bj5kkrQCrgEigsrXMK8uVdwxbYF0rOO2U1F5IgRU0jWq04JKphl1WL9fcQ4o_Z8iTGUJe5rYjxDkbLTVTUkhWyFd3kkQqLRiWivwfxVjrYquRBaUr6lLMOYE3hxQGm44FMotvszeLb7P4NpiVpUvRs1P-3A7Q_S05Cy7AixNgc_lZn-zoQv7HccobxUXhnq-ct9HYXSrMzdfSSWBMKJZ0mfrNSkCRcBsgmewCjA66kIp808Vw10v_AMgl1MY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1008826496</pqid></control><display><type>article</type><title>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</title><source>ScienceDirect Freedom Collection</source><creator>Gupta, Shalini ; Devanarayan, Viswanath ; Finco, Deborah ; Gunn, George R. ; Kirshner, Susan ; Richards, Susan ; Rup, Bonita ; Song, An ; Subramanyam, Meena</creator><creatorcontrib>Gupta, Shalini ; Devanarayan, Viswanath ; Finco, Deborah ; Gunn, George R. ; Kirshner, Susan ; Richards, Susan ; Rup, Bonita ; Song, An ; Subramanyam, Meena</creatorcontrib><description>The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007 [1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2011.03.038</identifier><identifier>PMID: 21531522</identifier><identifier>CODEN: JPBADA</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis ; Analytical, structural and metabolic biochemistry ; Animals ; Antibodies ; Antibodies, Neutralizing - immunology ; Antibody Formation ; Biological and medical sciences ; Biological Assay - methods ; Biological Products - immunology ; Blood Proteins - chemistry ; Cell-based assay ; Chemistry, Pharmaceutical - methods ; Chemistry, Pharmaceutical - standards ; Fundamental and applied biological sciences. Psychology ; General pharmacology ; Humans ; Immune response ; Immune System ; Immunogenicity assay ; Medical sciences ; NAb assay ; NAb assay validation ; neutralization ; Neutralization Tests ; neutralizing antibodies ; Neutralizing antibody bioassay ; Pharmaceutical Preparations ; Pharmacology. Drug treatments ; Reproducibility of Results ; Sensitivity and Specificity ; Serum-based bioassay ; Software ; therapeutics</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2011-07, Vol.55 (5), p.878-888</ispartof><rights>2011 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</citedby><cites>FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24249745$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21531522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Shalini</creatorcontrib><creatorcontrib>Devanarayan, Viswanath</creatorcontrib><creatorcontrib>Finco, Deborah</creatorcontrib><creatorcontrib>Gunn, George R.</creatorcontrib><creatorcontrib>Kirshner, Susan</creatorcontrib><creatorcontrib>Richards, Susan</creatorcontrib><creatorcontrib>Rup, Bonita</creatorcontrib><creatorcontrib>Song, An</creatorcontrib><creatorcontrib>Subramanyam, Meena</creatorcontrib><title>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007 [1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors.</description><subject>Analysis</subject><subject>Analytical, structural and metabolic biochemistry</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibody Formation</subject><subject>Biological and medical sciences</subject><subject>Biological Assay - methods</subject><subject>Biological Products - immunology</subject><subject>Blood Proteins - chemistry</subject><subject>Cell-based assay</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Chemistry, Pharmaceutical - standards</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune System</subject><subject>Immunogenicity assay</subject><subject>Medical sciences</subject><subject>NAb assay</subject><subject>NAb assay validation</subject><subject>neutralization</subject><subject>Neutralization Tests</subject><subject>neutralizing antibodies</subject><subject>Neutralizing antibody bioassay</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmacology. Drug treatments</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Serum-based bioassay</subject><subject>Software</subject><subject>therapeutics</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkV2L1DAUhoso7rj6B7zQ3IjedMx3UvBGFr9gQVAXvAtpejJmaJsxaRfGf-M_NaUzerdCICE85z05earqKcFbgol8vd_uD63dUkzIFrOy9L1qQ7RiNZX8-_1qgxUjtcJaXFSPct5jjAVp-MPqghLBiKB0U_3-Ai4OA4ydnUIcM_IxoekHoFvbh_UORY8c9H3d2gwdsjnbY0bzcj7DHUzgzuwI85RK9a8w7pAdp9DG7ojCMMwjoAT5UNpARtAHF6YlcGfDmCfUhtjHXXC2XzKTPZSc4PLj6oG3fYYnp_2yunn_7tvVx_r684dPV2-va8eVmGrGWy4bj5kkrQCrgEigsrXMK8uVdwxbYF0rOO2U1F5IgRU0jWq04JKphl1WL9fcQ4o_Z8iTGUJe5rYjxDkbLTVTUkhWyFd3kkQqLRiWivwfxVjrYquRBaUr6lLMOYE3hxQGm44FMotvszeLb7P4NpiVpUvRs1P-3A7Q_S05Cy7AixNgc_lZn-zoQv7HccobxUXhnq-ct9HYXSrMzdfSSWBMKJZ0mfrNSkCRcBsgmewCjA66kIp808Vw10v_AMgl1MY</recordid><startdate>20110715</startdate><enddate>20110715</enddate><creator>Gupta, Shalini</creator><creator>Devanarayan, Viswanath</creator><creator>Finco, Deborah</creator><creator>Gunn, George R.</creator><creator>Kirshner, Susan</creator><creator>Richards, Susan</creator><creator>Rup, Bonita</creator><creator>Song, An</creator><creator>Subramanyam, Meena</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7S9</scope><scope>L.6</scope><scope>7X8</scope></search><sort><creationdate>20110715</creationdate><title>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</title><author>Gupta, Shalini ; Devanarayan, Viswanath ; Finco, Deborah ; Gunn, George R. ; Kirshner, Susan ; Richards, Susan ; Rup, Bonita ; Song, An ; Subramanyam, Meena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Analysis</topic><topic>Analytical, structural and metabolic biochemistry</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibody Formation</topic><topic>Biological and medical sciences</topic><topic>Biological Assay - methods</topic><topic>Biological Products - immunology</topic><topic>Blood Proteins - chemistry</topic><topic>Cell-based assay</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Chemistry, Pharmaceutical - standards</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune System</topic><topic>Immunogenicity assay</topic><topic>Medical sciences</topic><topic>NAb assay</topic><topic>NAb assay validation</topic><topic>neutralization</topic><topic>Neutralization Tests</topic><topic>neutralizing antibodies</topic><topic>Neutralizing antibody bioassay</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmacology. Drug treatments</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Serum-based bioassay</topic><topic>Software</topic><topic>therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Shalini</creatorcontrib><creatorcontrib>Devanarayan, Viswanath</creatorcontrib><creatorcontrib>Finco, Deborah</creatorcontrib><creatorcontrib>Gunn, George R.</creatorcontrib><creatorcontrib>Kirshner, Susan</creatorcontrib><creatorcontrib>Richards, Susan</creatorcontrib><creatorcontrib>Rup, Bonita</creatorcontrib><creatorcontrib>Song, An</creatorcontrib><creatorcontrib>Subramanyam, Meena</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Shalini</au><au>Devanarayan, Viswanath</au><au>Finco, Deborah</au><au>Gunn, George R.</au><au>Kirshner, Susan</au><au>Richards, Susan</au><au>Rup, Bonita</au><au>Song, An</au><au>Subramanyam, Meena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2011-07-15</date><risdate>2011</risdate><volume>55</volume><issue>5</issue><spage>878</spage><epage>888</epage><pages>878-888</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><coden>JPBADA</coden><abstract>The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007 [1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>21531522</pmid><doi>10.1016/j.jpba.2011.03.038</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0731-7085
ispartof Journal of pharmaceutical and biomedical analysis, 2011-07, Vol.55 (5), p.878-888
issn 0731-7085
1873-264X
language eng
recordid cdi_proquest_miscellaneous_868376563
source ScienceDirect Freedom Collection
subjects Analysis
Analytical, structural and metabolic biochemistry
Animals
Antibodies
Antibodies, Neutralizing - immunology
Antibody Formation
Biological and medical sciences
Biological Assay - methods
Biological Products - immunology
Blood Proteins - chemistry
Cell-based assay
Chemistry, Pharmaceutical - methods
Chemistry, Pharmaceutical - standards
Fundamental and applied biological sciences. Psychology
General pharmacology
Humans
Immune response
Immune System
Immunogenicity assay
Medical sciences
NAb assay
NAb assay validation
neutralization
Neutralization Tests
neutralizing antibodies
Neutralizing antibody bioassay
Pharmaceutical Preparations
Pharmacology. Drug treatments
Reproducibility of Results
Sensitivity and Specificity
Serum-based bioassay
Software
therapeutics
title Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A28%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recommendations%20for%20the%20validation%20of%20cell-based%20assays%20used%20for%20the%20detection%20of%20neutralizing%20antibody%20immune%20responses%20elicited%20against%20biological%20therapeutics&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Gupta,%20Shalini&rft.date=2011-07-15&rft.volume=55&rft.issue=5&rft.spage=878&rft.epage=888&rft.pages=878-888&rft.issn=0731-7085&rft.eissn=1873-264X&rft.coden=JPBADA&rft_id=info:doi/10.1016/j.jpba.2011.03.038&rft_dat=%3Cproquest_cross%3E868376563%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1008826496&rft_id=info:pmid/21531522&rfr_iscdi=true